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patients revealed no signiﬁcant differences between 
compared therapeutic strategies. The study was aimed at 
analyzing the costs of alternative strategies to determine
effective allocation of limited resources. METHODS: A
cost minimization analysis was implemented because
both strategies are associated with similar clinical bene-
ﬁts. The retrospective costs for 205 patients randomly
assigned to studied groups were calculated over the time
horizon of 12 months. The costs of diagnostic and treat-
ment procedures, hospitalizations, out patients visits,
drugs and physicians’ consultations were estimated for
both groups using data gathered alongside clinical trial.
Expected costs, and incremental cost were identiﬁed. The
sensitivity analysis on unit cost driver items were per-
formed. The results are expressed in USD (PLN were
transformed by 2001 PPP value). RESULTS: The conser-
vative strategy with pharmacological ventricular rate
control was less costly then cardioversion and subsequent
sinus rhythm maintenance, 2850 USD (PPP) and 1350
USD, respectively. The cost driver contributing to
observed difference was the cost of cardioversion. Addi-
tional cost drivers were the cost of echocardiography, 24
hours ECG recording, cardiologists consultations, hospi-
talization costs including intensive care and cardiology
unit services. The sensitivity analysis performed on the
cost drivers conﬁrmed the domination of the conservative
strategy. CONCLUSIONS: The cardioversion and subse-
quent sinus rhythm maintenance in chronic atrial ﬁbril-
lation patients is more costly then pharmacological
ventricular rate control.
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OBJECTIVES: Percutaneous transluminal coronary
angioplasty (PTCA) is a common procedure in clinical
practice with more than 50,000 procedures performed
per year in Italy. There is evidence that aggressive lipid
lowering therapy reduces cardiovascular events, including
revascularization procedures. The objective of this analy-
sis is to evaluate the pharmacoeconomic proﬁle of aggres-
sive treatment with Atorvastatin compared to PTCA in
patients with PTCA indication, based on the results of the
AVERT study (Pitt et al. NEJM 1999). METHODS: Tech-
nique: Cost-effectiveness analysis. Using 2 hypothetical
cohorts of 1000 subjects, an incremental cost per patient
free from event has been calculated. Treatments: Ator-
vastatin (80mg/day) vs PTCA. Perspective: National
Health Service (NHS). Timeframe: 18 months. Costs:
Drugs and direct medical costs quantiﬁed by using NHS
tariffs expressed in Euro 2002. Effects: Cardiac death,
non-fatal acute myocardial infarction (AMI), coronary
artery bypass grafting (CABG), PTCA and angina.
RESULTS: The cost of aggressive Atorvastatin therapy
for 1000 subjects was €5.45 million vs €8.08 million for
the PTCA group. Aggressive Atorvastatin therapy was
more effective than PTCA with 75 additional event free
patients per 1000 treated. Safety proﬁles were similar in
both treatment groups with a comparable incidence 
of adverse events. CONCLUSIONS: This economic 
evaluation of the AVERT study shows that aggressive 
Atorvastatin therapy dominates PTCA, allowing a greater
number of patients to remain free of cardiovascular
events at a lower cost.
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OBJECTIVES: Percutaneous Transluminal Coronary
Angioplasty (PTCA) is widely used in Italy with more
than 50.000 procedures performed per year. However,
20–40% of subjects developed restenosis within 6 months
from the intervention. The objective of this analysis is the
assessment of the pharmacoeconomic proﬁle of Amlodip-
ine therapy after PTCA. METHODS: Patients and
setting: 2 hypothetical cohorts of 1000 patients treated
with Amlodipine besylate vs placebo after PTCA in Italy.
Perspective: National Health Service (NHS). Technique:
cost-effectiveness analysis; an incremental cost per patient
free from event has been calculated. Time: 4-months.
Costs: drugs and hospitalisations for cardiovascular dis-
eases (CVD) quantiﬁed by using NHS tariffs expressed in
Euro 2002. Clinical effects: measured through the results
of the CAPARES study (Jorgensen B et al, JACC 2000),
including death, acute myocardial infarction (AMI), 
coronary artery bypass grafting (CABG) and PTCA.
RESULTS: Treating the cohort of 1000 subjects with
Amlodipine resulted in a total cost of €1.052.258
(€146.084 for pharmacological therapy and €906.174 
for treating 100 CVD events). Treating the cohort of 
1000 subjects with placebo resulted in a total cost of
€1.376.351 to follow 164 CVD events. The treatment
with Amlodipine was more effective than placebo also
when considering the development of any ﬁrst CVD event
(94 with Amlodipine and 145 with placebo), with 51
additional event-free patients per 1000 treated. CON-
CLUSIONS: In a four month time horizon, Amlodipine
treatment is dominant over placebo because is less expen-
sive and more effective for prevention of CVD events in
patients who had PTCA.
